Ensysce Biosciences Inc (ENSC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 5,067 | 5,210 | 2,231 | 2,523 | 3,531 |
| Gross Profit | 5,067 | 5,210 | 2,231 | 2,523 | 3,531 |
| Operating Expenses | 15,308 | 11,940 | 12,949 | 26,746 | 23,402 |
| Operating Income | -10,241 | -6,730 | -10,718 | -24,222 | -19,870 |
| Interest Expense | 19 | 1,290 | 354 | 110 | 1,295 |
| Other Income | 84 | 34 | 446 | 124 | -7,980 |
| Pre-tax Income | -10,176 | -7,987 | -10,626 | -24,208 | -29,146 |
| Net Income Continuous | -10,176 | -7,987 | -10,626 | -24,208 | -29,146 |
| Minority Interests | -1 | 0 | -13 | -35 | -62 |
| Net Income | $-10,176 | $-7,987 | $-10,613 | $-24,172 | $-29,084 |
| EPS Basic Total Ops | -3.98 | -11.45 | -70.40 | -2,090.26 | -5,334.67 |
| EPS Basic Continuous Ops | -3.98 | -11.44 | -70.37 | -2,016.30 | -5,204.11 |
| EPS Diluted Total Ops | -3.98 | -11.45 | -70.40 | -2,090.26 | -5,334.67 |
| EPS Diluted Continuous Ops | -3.98 | -11.44 | -70.37 | -2,016.30 | -5,204.11 |
| EPS Diluted Before Non-Recurring Items | N/A | -11.45 | -70.32 | -2,116.59 | -5,327.47 |
| EBITDA(a) | $-10,234 | $-5,533 | $-10,392 | $-24,222 | $-19,870 |